Budesonide Nasal

DRUG5 trials

Conditions

AnosmiaBudesonideChronic Rhinosinusitis (Diagnosis)Environmental ExposureEpigenetic Effects of Intranasal SteroidsOlfaction DisordersParosmiaSARS-CoV-2

Phase 2

Ivermectin Nasal Drops in Post COVID-19 Parosmia

NCT05269030

Menoufia UniversityParosmia

Start: 2022-07-31End: 2023-03-31Target: 60Updated: 2022-05-11

Phase 3

Comparison of Topical Therapies in Post op Endoscopic Sinus Surgery Patients

WithdrawnNCT03303677

University of FloridaChronic Rhinosinusitis (Diagnosis)

Start: 2018-04-01End: 2019-11-01Updated: 2018-03-30

Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity

CompletedNCT04361474

Fondation Ophtalmologique Adolphe de RothschildAnosmia, Budesonide, Olfaction Disorders +1

Start: 2020-05-18End: 2021-06-25Updated: 2026-01-06

Phase 4

Epigenetic Health Benefits of Budesonide

Active, not recruitingNCT04342039

University of British ColumbiaEnvironmental Exposure, Epigenetic Effects of Intranasal Steroids

Start: 2021-01-07End: 2027-12-31Target: 20Updated: 2025-03-27

Unknown Phase

Use of Budesonide Diluted to Maximum Clinical Treatment of Patients With Chronic Rhinosinusitis With Polyoposis.

NCT05541419

Universidade Estadual de LondrinaChronic Rhinosinusitis (Diagnosis)

Start: 2018-08-10End: 2025-08-10Target: 60Updated: 2022-09-15

Related Papers

Local budesonide therapy in the management of persistent hyposmia in suspected non-severe COVID-19 patients: Results of a randomized controlled trial.

2023-08-293 citations

Efficacy of local budesonide therapy in the management of persistent hyposmia in COVID-19 patients without signs of severity: A structured summary of a study protocol for a randomised controlled trial.

2020-07-2011 citations